Detalhe da pesquisa
1.
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication.
Ann Oncol
; 32(10): 1245-1255, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34224826
2.
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).
Ann Oncol
; 30(5): 766-773, 2019 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30796821
3.
Safety of assisted reproductive techniques in young women harboring germline pathogenic variants in BRCA1/2 with a pregnancy after prior history of breast cancer.
ESMO Open
; 6(6): 100300, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34775302